PROS1 and COVID-19: After a single BNT162b2 dose, the level of anti-S-protein IgG was higher among older adults previously infected with COVID-19 than in those without a prior COVID-19 infection, indicating that one dose of the vaccine might be adequate in previously infected elderly individuals148.